Transcode Therapeutics (RNAZ) Accumulated Expenses (2021 - 2026)
Transcode Therapeutics' (RNAZ) quarterly Accumulated Expenses came in at $251180.0 in Q1 2026, up 19147.51% YoY from N/an in Q1 2025, and down 32.99% on a QoQ basis from $374850.0 in Q4 2025.
Transcode Therapeutics (RNAZ) Accumulated Expenses (2021 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 6 years of Accumulated Expenses data on file, last reported at $251180.0 in Q1 2026.
- Quarterly Accumulated Expenses rose 19147.51% year-over-year to $251180.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $251180.0 (up 19147.51% YoY) and the FY2025 annual result came in at $374850.0, up 185.4% from the prior year.
- Accumulated Expenses fell to $251180.0 in Q1 2026, from $374850.0 in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $589404.0 in Q4 2023 to a low of $1305.0 in Q1 2025.
- A 5-year average of $206195.2 and a median of $191532.0 in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2025 — Accumulated Expenses tumbled 99.36% — and 2026, when it surged 19147.51%.
- Tracing RNAZ's Accumulated Expenses over 5 years: stood at $164657.0 in 2022, then jumped by 257.96% to $589404.0 in 2023, then tumbled by 77.72% to $131342.0 in 2024, then soared by 185.4% to $374850.0 in 2025, then sank by 32.99% to $251180.0 in 2026.
- The last three Accumulated Expenses figures came in at $251180.0 (Q1 2026), $374850.0 (Q4 2025), and $216770.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 251,180.00 |
| Dec 31, 2025 | 374,850.00 |
| Sep 30, 2025 | 216,770.00 |
| Jun 30, 2025 | 187,322.00 |
| Mar 31, 2025 | 1,305.00 |
| Dec 31, 2024 | 131,342.00 |
| Sep 30, 2024 | 119,452.00 |
| Jun 30, 2024 | 191,532.00 |
| Mar 31, 2024 | 202,361.00 |
| Dec 31, 2023 | 589,404.00 |
| Sep 30, 2023 | 222,440.00 |
| Jun 30, 2023 | 312,242.00 |
| Mar 31, 2023 | 212,452.00 |
| Dec 31, 2022 | 164,657.00 |
| Sep 30, 2022 | 134,704.00 |
| Jun 30, 2022 | 119,929.00 |
| Mar 31, 2022 | 73,376.00 |
| Dec 31, 2021 | 482,237.00 |
| Sep 30, 2021 | 34,179.00 |